Shanghai, China

Zhengying Xi

This inventor holds 2 USPTO granted patents and 2 EPO patents. Top assignees: Cisen Pharmaceutical Co., Ltd., Medshine Discovery Inc.. Active years: 2023-2025.


% Patents Active = 100.0

 

Average Co-Inventor Count = 6.9

ph-index = 1


Company Filing History:


Years Active: 2023-2025

Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Innovations and Contributions of Inventor Zhengying Xi

Introduction

Zhengying Xi is a notable inventor based in Shanghai, China. He has made significant contributions to the field of pharmaceuticals, holding a total of 2 patents. His work focuses on developing innovative compounds that have potential therapeutic applications.

Latest Patents

Zhengying Xi's latest patents include a series of dimethylsulfoximine derivatives. This invention specifically discloses a compound represented by formula (II) and a pharmaceutically acceptable salt thereof. Another significant patent is for a diazaindole derivative, which is utilized as a CHK1 inhibitor. This patent outlines the use of the diazaindole derivative in the preparation of drugs for treating CHK1-related diseases.

Career Highlights

Throughout his career, Zhengying Xi has worked with prominent companies in the pharmaceutical industry. Notably, he has been associated with Medshine Discovery Inc. and Cisen Pharmaceutical Co., Ltd. His work in these organizations has contributed to advancements in drug discovery and development.

Collaborations

Zhengying Xi has collaborated with esteemed colleagues, including Yonggang Liao and Wenyuan Qian. These partnerships have fostered innovation and have been instrumental in his research endeavors.

Conclusion

Zhengying Xi's contributions to the field of pharmaceuticals through his patents and collaborations highlight his role as an influential inventor. His work continues to pave the way for advancements in medical treatments and drug development.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…